share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K：外国发行人报告
美股sec公告 ·  07/01 08:08
Moomoo AI 已提取核心信息
NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.
NeuroSense Therapeutics Ltd., a biotechnology company, announced on July 1, 2024, significant findings from their 12-month PARADIGM Phase 2b study of PrimeC, a treatment for Amyotrophic Lateral Sclerosis (ALS). The study demonstrated a 36% improvement in disease progression and a 43% better survival rate for participants receiving PrimeC compared to those on placebo. The results, which also showed a 63% improvement in survival in a per-protocol analysis, suggest PrimeC's potential as a disease-modifying drug. NeuroSense is now planning a Phase 3 clinical study in the U.S. and Europe. The company's strategy focuses on developing therapies that target multiple pathways of neurodegenerative diseases. PrimeC has been granted Orphan Drug Designation in the U.S. and EU. NeuroSense uses its website and social media channels to distribute information to investors, who are advised to monitor these channels along with SEC filings and press releases.
生物技术公司NeuroSense Therapeutics Ltd.于2024年7月1日宣布，其PrimeC治疗肌萎缩侧索硬化症（ALS）的12个月PARADIGM 2b期研究取得重大成果。该研究表明，相对于安慰剂患者，接受PrimeC治疗的参与者疾病进展率减少了36％，生存率提高了43％。该结果还显示，在符合方案分析中，生存率提高了63％，表明PrimeC具有作为疾病修饰药物的潜力。 NeuroSense现计划在美国和欧洲进行第三阶段临床研究。该公司的策略是开发针对神经退行性疾病多个途径的治疗方案。PrimeC已在美国和欧盟获得孤儿药物认定。 NeuroSense使用其网站和社交媒体渠道向投资者分发信息，建议投资者监测这些渠道以及SEC文件和新闻发布。
生物技术公司NeuroSense Therapeutics Ltd.于2024年7月1日宣布，其PrimeC治疗肌萎缩侧索硬化症（ALS）的12个月PARADIGM 2b期研究取得重大成果。该研究表明，相对于安慰剂患者，接受PrimeC治疗的参与者疾病进展率减少了36％，生存率提高了43％。该结果还显示，在符合方案分析中，生存率提高了63％，表明PrimeC具有作为疾病修饰药物的潜力。 NeuroSense现计划在美国和欧洲进行第三阶段临床研究。该公司的策略是开发针对神经退行性疾病多个途径的治疗方案。PrimeC已在美国和欧盟获得孤儿药物认定。 NeuroSense使用其网站和社交媒体渠道向投资者分发信息，建议投资者监测这些渠道以及SEC文件和新闻发布。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息